已发表论文

心血管疾病中的CaMK II,特别是CaMK II-δ:朋友还是敌人

 

Authors Tan YQ, Zhang W, Xie ZC, Li J, Chen HW

Received 11 April 2024

Accepted for publication 5 July 2024

Published 5 August 2024 Volume 2024:18 Pages 3461—3476

DOI https://doi.org/10.2147/DDDT.S473251

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Professor Anastasios Lymperopoulos

Yu-Qing Tan,1,* Wang Zhang,2,* Zi-Cong Xie,1 Jun Li,1 Heng-Wen Chen3 

1Department of Cardiology, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, 100053, People’s Republic of China; 2Department of Pharmacy, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, 100053, People’s Republic of China; 3New Drug Research and Development Office, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, 100053, People’s Republic of China

*These authors contributed equally to this work

Correspondence: Jun Li; Heng-Wen Chen, Email 13051458913@163.com; chenhengwen@163.com

Abstract: Cardiovascular diseases (CVDs) tend to affect the young population and are associated with a significant economic burden and psychological distress to the society and families. The physiological and pathological processes underlying CVDs are complex. Ca2+/calmodulin-dependent kinase II (CaMK II), a protein kinase, has multiple biological functions. It participates in multiple pathological processes and plays a central role in the development of CVDs. Based on this, this paper analyzes the structural characteristics and distribution of CaMK II, the mechanism of action of CaMK II, and the relationship between CaMK II and CVDs, including ion channels, ischemia-reperfusion injury, arrhythmias, myocardial hypertrophy, cardiotoxicity, hypertension, and dilated cardiomyopathy. Given the different regulatory mechanisms of different isoforms of CaMK II, the clinical use of specific targeted inhibitors or novel compounds should be evaluated in future research to provide new directions.

Keywords: CaMK II, cardiovascular diseases, ischemia-reperfusion injury, arrhythmias, myocardial hypertrophy